Unión Europea -
noruego -
EMA (European Medicines Agency)
ondexxya
astrazeneca ab - andexanet alfa - narkotika-relaterte bivirkninger og uønskede reaksjoner - alle andre terapeutiske produkter - for voksne pasienter behandlet med en direkte faktor xa (anl) inhibitor (apixaban eller rivaroxaban) når reversering av antikoagulasjonsbehandling er nødvendig på grunn av livstruende eller ukontrollert blødning.
Unión Europea -
noruego -
EMA (European Medicines Agency)
ervebo
merck sharp & dohme b.v. - rekombinant vesicular stomatitis virus (belastning indiana) med en sletting av konvolutten glykoprotein, erstattet med zaire ebolavirus (belastning kikwit 1995) overflate glykoprotein - hemoragisk feber, ebola - vaksiner - ervebo is indicated for active immunization of individuals 1 year of age or older to protect against ebola virus disease (evd) caused by zaire ebola virus. bruk av ervebo skal være i samsvar med offisielle anbefalinger.
Unión Europea -
noruego -
EMA (European Medicines Agency)
vaxchora
bavarian nordic a/s - vibrio cholerae, belastning cvd 103-hgr, live - kolera - vaksiner - vaxchora is indicated for active immunisation against disease caused by vibrio cholerae serogroup o1 in adults and children aged 2 years and older. denne vaksinen skal brukes i samsvar med offisielle anbefalinger.
Unión Europea -
noruego -
EMA (European Medicines Agency)
fluad tetra
seqirus netherlands b.v. - a/darwin/9/2021 (h3n2) - like strain (a/darwin/6/2021, ivr-227) / a/victoria/4897/2022 (h1n1) pdm09-like strain (a/victoria/4897/2022, ivr-238) / b/phuket/3073/2013-like strain (b/phuket/3073/2013, bvr-1b) / influenza virus b/austria/1359417/2021-like strain (b/austria/1359417/2021, bvr-26) - influensa, human - vaksiner - forebygging av influensa hos eldre (65 år og eldre). fluad tetra bør brukes i samsvar med offisielle anbefalinger.
Unión Europea -
noruego -
EMA (European Medicines Agency)
fingolimod accord
accord healthcare s.l.u. - fingolimod hydrochloride - multippel sklerose, relapsing-remitting - immunosuppressants, selektiv immunosuppressants - angitt som enkelt sykdom endre terapi i svært aktive relapsing remitting multippel sklerose for følgende grupper av voksne pasienter og paediatric pasienter i alderen 10 år og eldre:pasienter med svært aktiv sykdom til tross for en fullstendig og adekvat løpet av behandlingen med minst én sykdom endre therapyorpatients med raskt utviklende alvorlig relapsing remitting multippel sklerose definert ved 2 eller flere deaktivere tilbakefall i ett år, og med 1 eller flere gadolinium å styrke lesjoner på brain mr eller en betydelig økning i t2 lesjon legg i forhold til en tidligere nyere mr.
Unión Europea -
noruego -
EMA (European Medicines Agency)
comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaksiner - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. bruk av denne vaksinen skal være i samsvar med offisielle anbefalinger.
Unión Europea -
noruego -
EMA (European Medicines Agency)
jcovden (previously covid-19 vaccine janssen)
janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vaksiner - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. bruk av denne vaksinen skal være i samsvar med offisielle anbefalinger.
Unión Europea -
noruego -
EMA (European Medicines Agency)
vaxzevria (previously covid-19 vaccine astrazeneca)
astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vaksiner - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. bruk av denne vaksinen skal være i samsvar med offisielle anbefalinger.
